全文获取类型
收费全文 | 5791篇 |
免费 | 437篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 114篇 |
妇产科学 | 81篇 |
基础医学 | 1094篇 |
口腔科学 | 122篇 |
临床医学 | 512篇 |
内科学 | 1139篇 |
皮肤病学 | 171篇 |
神经病学 | 665篇 |
特种医学 | 225篇 |
外科学 | 471篇 |
综合类 | 16篇 |
一般理论 | 6篇 |
预防医学 | 574篇 |
眼科学 | 134篇 |
药学 | 338篇 |
中国医学 | 15篇 |
肿瘤学 | 534篇 |
出版年
2024年 | 8篇 |
2023年 | 63篇 |
2022年 | 106篇 |
2021年 | 190篇 |
2020年 | 120篇 |
2019年 | 161篇 |
2018年 | 159篇 |
2017年 | 179篇 |
2016年 | 193篇 |
2015年 | 233篇 |
2014年 | 259篇 |
2013年 | 336篇 |
2012年 | 505篇 |
2011年 | 509篇 |
2010年 | 287篇 |
2009年 | 275篇 |
2008年 | 390篇 |
2007年 | 419篇 |
2006年 | 366篇 |
2005年 | 356篇 |
2004年 | 296篇 |
2003年 | 285篇 |
2002年 | 230篇 |
2001年 | 35篇 |
2000年 | 26篇 |
1999年 | 36篇 |
1998年 | 39篇 |
1997年 | 36篇 |
1996年 | 18篇 |
1995年 | 18篇 |
1994年 | 23篇 |
1993年 | 15篇 |
1992年 | 9篇 |
1991年 | 4篇 |
1990年 | 4篇 |
1989年 | 8篇 |
1987年 | 3篇 |
1985年 | 8篇 |
1984年 | 4篇 |
1983年 | 3篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1977年 | 5篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1959年 | 1篇 |
排序方式: 共有6245条查询结果,搜索用时 15 毫秒
991.
Linn Woelber Sabrina Mathey Katharina Prieske Sascha Kuerti Christoph Hillen Eike Burandt Anja Coym Volkmar Mueller Barbara Schmalfeldt Anna Jaeger 《Oncology research》2021,28(6):645
Therapeutic options in recurrent or metastasized vulvar squamous cell cancer (VSCC) not amenable to radiotherapy or radical surgery are limited. Evidence for the use of targeted therapies is sparse. All patients with VSCC treated at the Gynecological Cancer Center Hamburg-Eppendorf 2013–2019 were retrospectively evaluated for targeted therapeutic approaches. Furthermore, a MEDLINE, EMBASE, Web of Science, Scopus, and OVID database search was performed using the terms: “vulvar cancer” AND “targeted therapy,” “erlotinib,” “EGFR,” “bevacizumab,” “VEGF,” “pembrolizumab,” or “immunotherapy.” Twelve of 291 patients (4.1%) with VSCC received at least one targeted therapy at our institution. Previously, one or more platinum-based chemotherapy was applied to all patients [median 3.5 previous lines (range 2–5)]. In the erlotinib subgroup, two of five patients (40%) achieved stable disease (SD), while two patients (2/5, 40%) experienced partial response (PR). Treatment was given as monotherapy in second/third line for a median of 3.4 months (range 2–6 months). Bevacizumab (n = 9) was given as maintenance therapy after platinum-based first-line chemotherapy (9/9); best response was complete response (CR) (n = 2/9 22.2%). Median duration of treatment was 7 months (range 4–13 months) with two patients still under ongoing treatment. Best response in the pembrolizumab (n = 3) subset was SD (n = 1/3 33%). Treatment was given as monotherapy in second/third line for a median of 3.3 months (range 3–4 months). Nine of 12 patients (75%) experienced treatment-related adverse events (TRAEs), most commonly grade 1/2. Rapidly evolving antibody treatments have proven clinical benefit especially in HPV-driven tumor entities; however, clinical investigations in VSCC are still limited. These reported cases provide evidence for the clinical utility and feasibility while ensuring an acceptable safety profile.Key words: Vulvar cancer (VC), Targeted therapy, EGFR targeting, VEGF signaling pathway, Immuno-oncology 相似文献
992.
Lukas Wisgrill Anja Weinhandl Lukas Unterasinger Gabriele Amann Rudolf Oehler Martin L. Metzelder Angelika Berger Thomas M. Benkoe 《Journal of pediatric surgery》2019,54(3):449-454
Background
Symptoms at suspicion of necrotizing enterocolitis (NEC) are often nonspecific and several biomarkers have been evaluated for their discriminative power to both diagnose and predict the course from NEC suspicion to complicated disease requiring surgical intervention. Thus, we aimed to assess the utility of interleukin-6 (IL-6) to predict surgical intervention in infants suffering from NEC and, furthermore, to discriminate infants with starting NEC or late-onset sepsis (LOS).Methods
IL-6 serum levels at disease onset were retrospectively analyzed in 24 infants suffering from NEC as well as 16 neonates with LOS.Results
IL-6 serum levels at disease onset were significantly higher in infants suffering from NEC necessitating surgical intervention in the disease course compared to infants with medical NEC (5000 [785–5000] vs. 370 [78–4716] pg/ml, p?=?0.0008) as well as gram-positive LOS (5000 [785–5000] vs. 84 [12–269] pg/ml, p?=?0.0001). Infants suffering from gram-negative LOS exhibited elevated IL-6 serum levels at disease onset comparable to infants with surgical NEC (5000 [1919–5000] vs. 5000 [785–5000] pg/ml, p?=?1.00).Conclusion
The proinflammatory cytokine IL-6 appears to be a promising marker to distinguish surgical NEC from medical NEC at the onset of disease but cannot discriminate between surgical NEC and gram-negative LOS.Level of evidence
II 相似文献993.
Maren Gebbing Thorsten Bergmann Eric Schulz Anja Ehrhardt 《World journal of hepatology》2015,7(2):150-164
Acute and chronic hepatitis B virus(HBV) infections remain to present a major global health problem. The infection can be associated with acute symptomatic or asymptomatic hepatitis which can cause chronic inflammation of the liver and over years this can lead to cirrhosis and the development of hepatocellularcarcinomas. Currently available therapeutics for chronically infected individuals aim at reducing viral replication and to slow down or stop the progression of the disease. Therefore, novel treatment options are needed to efficiently combat and eradicate this disease. Here we provide a state of the art overview of gene therapeutic approaches to inhibit HBV replication. We discuss non-viral and viral approaches which were explored to deliver therapeutic nucleic acids aiming at reducing HBV replication. Types of delivered therapeutic nucleic acids which were studied since many years include antisense oligodeoxynucleotides and antisense RNA, ribozymes and DNAzymes, RNA interference, and external guide sequences. More recently designer nucleases gained increased attention and were exploited to destroy the HBV genome. In addition we mention other strategies to reduce HBV replication based on delivery of DNA encoding dominant negative mutants and DNA vaccination. In combination with available cell culture and animal models for HBV infection, in vitro and in vivo studies can be performed to test efficacy of gene therapeutic approaches. Recent progress but also challenges will be specified and future perspectives will be discussed. This is an exciting time to explore such approaches because recent successes of gene therapeutic strategies in the clinic to treat genetic diseases raise hope to find alternative treatment options for patients chronically infected with HBV. 相似文献
994.
995.
Study protocol for ‘we DECide’: implementation of advance care planning for nursing home residents with dementia 下载免费PDF全文
996.
Jenni Jaakkola Anja Rantanen Pauliina Luopa Anna‐Maija Koivisto Katja Joronen 《Scandinavian journal of caring sciences》2019,33(1):144-155
This article examines the self‐rated health, symptoms and health behaviour of upper secondary vocational students in Finland. The data consist of the responses of first‐ and second‐year vocational students (n = 34 554) to the 2013 School Health Promotion Survey. The data were analysed statistically and processed separately for girls and boys. Associations between self‐rated health, symptoms and health behaviour and fields of study were examined by cross‐tabulation. Statistical significance was measured using the chi‐squared test. Self‐rated health, symptoms and health behaviour were found to have a statistically significant association with field of study (p < 0.001). Vocational students in different fields had different experiences of health, different symptoms and different health behaviours. The results complement existing evidence about disparities in well‐being among young people in the context of education. 相似文献
997.
Ramona Schuppner Justus Maehlmann Meike Dirks Hans Worthmann Anita B. Tryc Kajetan Sandorski Elisabeth Bahlmann Jan T. Kielstein Anja M. Giesemann Heinrich Lanfermann Karin Weissenborn 《Medicine》2016,95(6)
In an outbreak of shiga toxin-producing Escherichia coli infections and associated hemolytic-uremic syndrome (STEC O104:H4) in Germany in the year 2011 neurological complications in adult patients occurred unexpectedly frequent, ranging between 48% and 100% in different patient groups. Few is known about the long-term effects of such complications and so we performed follow-up exams on 44 of the patients treated for STEC-HUS at Hannover Medical Scool in this observational study. Standardized follow-up exams including neurological and neuropsychological assessments, laboratory testing, magnetic resonance imaging (MRI), and EEG were carried out. Subgroups were examined 2 (n = 34), 7 (n = 22), and 19 (n = 23) months after disease onset. Additionally, at the 19-month follow-up, quality of life, sleep quality, and possible fatigue were assessed.Nineteen months after disease onset 31 patients were reassessed, 22 of whom still suffered from symptoms such as fatigue, headache, and attention deficits. In the neuropsychological assessments only 39% of the patients performed normal, whereas 61% scored borderline pathological or lower. Upon reviewal, the follow-up data most prominently showed a secondary decline of cognitive function in about one-quarter of the patients. Outcome was not related to treatment or laboratory data in the acute phase of the disease nor length of hospitalization. Prognosis of STEC-HUS associated brain dysfunction in adults with regard to severity of symptoms is mostly good; some patients however still have not made a full recovery. Patients’ caretakers have to be aware of possible secondary decline of brain function as was observed in this study. 相似文献
998.
999.
Rick L. Haas Suzanne van Beek Anja Betgen Shaheen Ali Christoph J. Schneider Fenna Heres Diddens Astrid N. Scholten Folkert Koetsveld Peter Remeijer 《Practical radiation oncology》2019,9(2):115-122